Head and neck cancerVeröffentlicht am: 3. Juni 2019
ASCO 2019: Promising therapy for HER2-amplified salivary gland cancers
Ado-trastuzumab emtansine represents a feasible treatment strategy for patients with advanced SGT and shows early evidence of activity in a subset of patients.
